NCT02391259View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

November 30, 2011

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

AMG 557

AMG 557 is for the treatment of sybjects with systemic lupus erythematosus

DRUG

Placebo

contains no active drug

Trial Locations (13)

10003

Research Site, New York

11030

Research Site, Manhasset

14642

Research Site, Rochester

16635

Research Site, Duncansville

36207

Research Site, Anniston

46360

Research Site, Michigan City

75231

Research Site, Dallas

75247

Research Site, Dallas

85013

Research Site, Phoenix

90033

Research Site, Los Angeles

90048

Research Site, Los Angeles

02747

Research Site, North Dartmouth

NW10 7NS

Research Site, London

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02391259 - A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter